Telix GM 2024
Telix’s 2024 GM was held on Friday, 5th April 2024 at The Wesley Conference Centre in Sydney, Australia and…
Read moreNews & Views
Telix to Present Phase III ProstACT GLOBAL Study (TLX591 Therapy) and Phase II STARBURST Study (TLX250-CDx Indication Expansion) at EAU
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s late-stage theranostic programs at the 39th Annual European Association of Urology Congress (EAU24), Europe’s largest urological…
Read more
World First Use of Lightpoint’s SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix’s miniature…
Read more
First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
Telix today announces that the first patient has been dosed in its named patient program in Italy for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®). TLX250-CDx is the Company’s investigational non-invasive carbonic anhydrase IX…
Read more
QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical…
Read more
Appointment of Dr Darren Patti to Group Chief Operating Officer
ASX,
Telix is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March…
Read more
Notice of General Meeting
ASX,
Telix today announces a general meeting of shareholders to be held at The Wesley Conference Centre, Lyceum Room, 220 Pitt Street, Sydney, NSW 2000 and online via https://meetings.linkgroup.com/TLXGM24 on Friday…
Read more
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
Telix today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure…
Read more
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
Telix today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics…
Read more
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
Telix today announces its financial results for the financial year ended 31 December 2023….
Read more